171 related articles for article (PubMed ID: 29449735)
1. ALK-positive adenocarcinoma of the lung expressing neuroendocrine markers and presenting as a "pituitary adenoma".
Mengoli MC; Bertolini F; Maur M; Barbieri F; Longo L; Gasparri P; Tiseo M; Rossi G
Pathologica; 2017 Dec; 109(4):408-411. PubMed ID: 29449735
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
3. Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors.
Sim J; Kim H; Hyeon J; Choi Y; Han J
J Korean Med Sci; 2018 Apr; 33(15):e123. PubMed ID: 29629521
[TBL] [Abstract][Full Text] [Related]
4. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
[TBL] [Abstract][Full Text] [Related]
5. Ovarian Metastases from ALK-rearranged Lung Adenocarcinoma: A Case Report and Literature Review.
Sasano H; Sekine A; Hirata T; Iwamoto K; Itou Y; Itani H; Kondou S; Tokui T; Tanigawa M
Intern Med; 2018 Nov; 57(22):3271-3275. PubMed ID: 29984766
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma.
Koyama K; Katsurada N; Jimbo N; Tachihara M; Tamura D; Nakata K; Nagano T; Yamamoto M; Kamiryo H; Kobayashi K; Itoh T; Nishimura Y
Pathol Int; 2019 May; 69(5):294-299. PubMed ID: 30900377
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.
Gupta R; Amanam I; Rahmanuddin S; Mambetsariev I; Wang Y; Huang C; Reckamp K; Vora L; Salgia R
Am J Clin Oncol; 2019 Apr; 42(4):337-344. PubMed ID: 30741758
[TBL] [Abstract][Full Text] [Related]
8. VIT-ALK, a Novel Alectinib-Sensitive Fusion Gene in Lung Adenocarcinoma.
Hu S; Li Q; Peng W; Feng C; Zhang S; Li C
J Thorac Oncol; 2018 May; 13(5):e72-e74. PubMed ID: 29703539
[No Abstract] [Full Text] [Related]
9. Role of imaging biomarkers in predicting anaplastic lymphoma kinase-positive lung adenocarcinoma.
Jeong CJ; Lee HY; Han J; Jeong JY; Lee KS; Choi YL; Choi JY
Clin Nucl Med; 2015 Jan; 40(1):e34-9. PubMed ID: 25243942
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact and distinctive characteristics of surgically resected anaplastic lymphoma kinase-rearranged lung adenocarcinoma.
Matsuura Y; Ninomiya H; Ichinose J; Nakao M; Okumura S; Nishio M; Mun M
J Thorac Cardiovasc Surg; 2022 Feb; 163(2):441-451.e1. PubMed ID: 33131892
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma.
Caumont C; Veillon R; Gros A; Laharanne E; Bégueret H; Merlio JP
Lung Cancer; 2016 Feb; 92():15-8. PubMed ID: 26775590
[TBL] [Abstract][Full Text] [Related]
12. Response of a Novel KANK1::ALK Fusion to Alectinib in an Advanced Lung Adenocarcinoma: A Case Report.
Tang Q; Li T; Ren F; Li X; Cao W; Yu H; Mao F; Cao C; Zu L; Xu S
J Natl Compr Canc Netw; 2024 Feb; 22(2):. PubMed ID: 38364363
[TBL] [Abstract][Full Text] [Related]
13. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
[TBL] [Abstract][Full Text] [Related]
14. GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
Jiang J; Wu X; Tong X; Wei W; Chen A; Wang X; Shao YW; Huang J
Lung Cancer; 2018 Jan; 115():5-11. PubMed ID: 29290262
[TBL] [Abstract][Full Text] [Related]
15. ALK-rearranged lung cancer with intradural extramedullary spinal cord metastases responding to ceritinib treatment: A case report.
Xu Y; Zhong W; Chen M; Zhao J; Wang M
Thorac Cancer; 2018 Aug; 9(8):1078-1081. PubMed ID: 29862659
[TBL] [Abstract][Full Text] [Related]
16. Small-cell transformation of
Balla A; Khan F; Hampel KJ; Aisner DL; Sidiropoulos N
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29317428
[TBL] [Abstract][Full Text] [Related]
17. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
Califano R; Greystoke A; Lal R; Thompson J; Popat S
Lung Cancer; 2017 Sep; 111():51-58. PubMed ID: 28838397
[TBL] [Abstract][Full Text] [Related]
18. Individualized nomogram for predicting ALK rearrangement status in lung adenocarcinoma patients.
Song L; Zhu Z; Wu H; Han W; Cheng X; Li J; Du H; Lei J; Sui X; Song W; Jin ZY
Eur Radiol; 2021 Apr; 31(4):2034-2047. PubMed ID: 33146791
[TBL] [Abstract][Full Text] [Related]
19. A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-Small-Cell Lung Cancer.
Biya J; Caramella C; Lindsay CR; Planchard D; Besse B
J Thorac Oncol; 2015 Jun; 10(6):e44-5. PubMed ID: 26001149
[TBL] [Abstract][Full Text] [Related]
20. [Molecular diagnostics of ALK-positive lung cancer].
Tímár J; Lotz G; Rásó E; Moldvay J
Magy Onkol; 2017 Sep; 61(3):301-311. PubMed ID: 28931104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
